Collectins, H-ficolin and LL-37 reduce influence viral replication in human monocytes and modulate virus-induced cytokine production

Innate Immunity

Volumn 23, Issue 1, 2017, Pages 77-88

  White, Mitchell R ^a   Tripathi, Shweta ^a   Verma, Anamika ^a   Kingma, Paul ^b   Takahashi, Kazue ^c   Jensenius, Jens ^d   Thiel, Steffen ^d   Wang, Guangshun ^e   Crouch, Erika C ^f   Hartshorn, Kevan L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d AARHUS UNIVERSITY   (Denmark)

^e NEBRASKA MEDICAL CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antimicrobial peptide; Neutrophil; pandemic; phagocyte; TNF

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLLECTIN; CYTOKINE; H FICOLIN; M FICOLIN; MANNOSE BINDING LECTIN; SURFACTANT PROTEIN D; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; FCN3 PROTEIN, HUMAN; GLYCOPROTEIN; LECTIN; PROTEIN BINDING;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); MONOCYTE; NEUTROPHIL; NONHUMAN; PROTEIN STRUCTURE; VIRAL CLEARANCE; VIRUS REPLICATION; CELL CULTURE; GENETICS; IMMUNOLOGY; INFLUENZA; INNATE IMMUNITY; METABOLISM; PHAGOCYTOSIS; PHYSIOLOGY; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; RESPIRATORY MUCOSA; VIROLOGY; VIRUS LOAD;

ANTIMICROBIAL CATIONIC PEPTIDES; CELLS, CULTURED; COLLECTINS; GLYCOPROTEINS; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LECTINS; NEUTROPHILS; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RESPIRATORY MUCOSA; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS REPLICATION;

EID: 85006716733     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425916678470     Document Type: Article

References (52)

1. Tripathi S, White MR, Hartshorn KL,. The amazing innate immune response to influenza A virus infection. Innate Immun 2015; 21: 73-98.
2. Ghoneim HE, Thomas PG, McCullers JA,. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 2013; 191: 1250-1259.
3. Tate MD, Brooks AG, Reading PC,. Specific sites of N-linked glycosylation on the hemagglutinin of H1N1 subtype influenza A virus determine sensitivity to inhibitors of the innate immune system and virulence in mice. J Immunol 2012; 187: 1884-1894.
4. Kim HM, Lee YW, Lee KJ, et al. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. J Virol 2008; 82: 4265-4274.
5. Nelson B, Zhou X, White M, et al. Recombinant human mannose-binding lectin dampens human alveolar macrophage inflammatory responses to influenza A virus in vitro. J Leukoc Biol. Epub ahead of print 7 January 2014.
6. Gong D, Farley K, White M, et al. Critical role of serpinB1 in regulating inflammatory responses in pulmonary influenza infection. J Infect Dis 2011; 204: 592-600.
7. Lin KL, Sweeney S, Kang BD, et al. CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol 2011; 186: 508-515.
8. Lin KL, Suzuki Y, Nakano H, et al. CCR2 + monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 2008; 180: 2562-2572.
9. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 2009; 106: 3455-3460.
10. Perrone LA, Plowden JK, Garcia-Sastre A, et al. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLOS Pathog 2008; 4: e1000115-e1000115.
11. Kobasa D, Jones SM, Shinya K, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007; 445: 319-323.
12. Tumpey TM, Garcia-Sastre A, Taubenberger JK, et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 2005; 79: 14933-14944.
13. Aldridge JR Jr., Moseley CE, Boltz DA, et al. TNF-A /iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009; 106: 5306-5311.
14. Xu L, Yoon H, Zhao MQ, et al. Cutting edge: pulmonary immunopathology mediated by antigen-specific expression of TNF-A -alpha by antiviral CD8 + T cells. J Immunol 2004; 173: 721-725.
15. Hussell T, Pennycook A, Openshaw PJ,. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 2001; 31: 2566-2573.
16. Hayden F, Fritz R, Lobo M, et al. Local and systemic cytokine response during experimental human influenza A virus infection. J Clin Invest 1998; 101: 643-649.
17. Hartshorn KL,. Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Front Biosci (Schol Ed) 2010; 2: 527-546.
18. Chang WC, White MR, Moyo P, et al. Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC Immunol 2010; 11: 64-64.
19. Reading PC, Morey LS, Crouch EC, Anders EM,. Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J Virol 1997; 71: 8204-8212.
20. Hawgood S, Brown C, Edmondson J, et al. Pulmonary collectins modulate strain-specific influenza a virus infection and host responses. J Virol 2004; 78: 8565-8572.
21. Li G, Siddiqui J, Hendry M, et al. Surfactant protein-A-deficient mice display an exaggerated early inflammatory response to a beta-resistant strain of influenza A virus. Am J Respir Cell Mol Biol 2002; 26: 277-282.
22. Kalman RS, Hartshorn K, Farraye FA,. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 2015; 21: 428-435.
23. LeVine AM, Hartshorn K, Elliott J, et al. Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol 2002; 282: L563-L572.
24. LeVine AM, Whitsett JA, Hartshorn KL, et al. Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 2001; 167: 5868-5873.
25. Hartl D, Griese M,. Surfactant protein D in human lung diseases. Eur J Clin Invest 2006; 36: 423-435.
26. Pan Q, Chen H, Wang F, et al. L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun 2012; 4: 312-324.
27. Verma A, White M, Vathipadiekal V, et al. Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses. J Immunol 2012; 189: 2478-2487.
28. Hartshorn KL, Crouch EC, White MR, et al. Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J Clin Invest 1994; 94: 311-319.
29. Munthe-Fog L, Hummelshoj T, Honore C, et al. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med 2009; 360: 2637-2644.
30. Frankenberger M, Schwaeble W, Ziegler-Heitbrock L,. Expression of M-Ficolin in human monocytes and macrophages. Mol Immunol 2008; 45: 1424-1430.
31. Tripathi S, Tecle T, Verma A, et al. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J Gen Virol 2013; 94: 40-49.
32. Barlow PG, Svoboda P, Mackellar A, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLOS ONE 2011; 6: e25333-e25333.
33. Doss M, White MR, Tecle T, et al. Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. J Immunol 2009; 182: 7878-7887.
34. Salvatore M, Garcia-Sastre A, Ruchala P, et al. alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J Infect Dis 2007; 196: 835-843.
35. Putsep K, Carlsson G, Boman HG, Andersson M,. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002; 360: 1144-1149.
36. Hartshorn K, Chang D, Rust K, et al. Interactions of recombinant human pulmonary surfactant protein D and SP-D multimers with influenza A. Am J Physiol 1996; 271: L753-L762.
37. White M, Kingma P, Tecle T, et al. Multimerization of surfactant protein D, but not its collagen domain, is required for antiviral and opsonic activities related to influenza virus. J Immunol 2008; 181: 7936-7943.
38. Kingma PS, Zhang L, Ikegami M, et al. Correction of pulmonary abnormalities in Sftpd-/- mice requires the collagenous domain of surfactant protein D. J Biol Chem 2006; 281: 24496-24505.
39. Zacho RM, Jensen L, Terp R, et al. Studies of the pattern recognition molecule H-ficolin: specificity and purification. J Biol Chem 2012; 287: 8071-8081.
40. Michelow IC, Dong M, Mungall BA, et al. A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J Biol Chem 2010; 285: 24729-24739.
41. Hartshorn KL, Collamer M, Auerbach M, et al. Effects of influenza A virus on human neutrophil calcium metabolism. J Immunol 1988; 141: 1295-1301.
42. Qi L, Kash JC, Dugan VG, et al. The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding. Virology 2011; 412: 426-434.
43. Hartshorn KL, White MR, Shepherd V, Reid K, Jensenius JC, Crouch EC,. Mechanisms of anti-influenza activity of surfactant proteins A and D: comparison with serum collectins. Am J Physiol 1997; 273: L1156-L1166.
44. Nikolaidis NM, White MR, Allen K, et al. Mutations flanking the carbohydrate binding site of surfactant protein D confer antiviral activity for pandemic influenza A viruses. Am J Physiol Lung Cell Mol Physiol 2014; 306: L1036-L1044.
45. Crouch E, Nikolaidis N, McCormack FX, et al. Mutagenesis of surfactant protein D informed by evolution and x-ray crystallography enhances defenses against influenza A virus in vivo. J Biol Chem 2011; 286: 40681-40692.
46. Crouch E, Hartshorn K, Horlacher T, et al. Recognition of mannosylated ligands and influenza A virus by human surfactant protein D: contributions of an extended site and residue 343. Biochemistry 2009; 48: 3335-3345.
47. Chang WC, Hartshorn KL, White MR, et al. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem Pharmacol 2011; 81: 388-395.
48. Takahashi K, Moyo P, Chigweshe L, et al. Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res 2013; 178: 495-501.
49. Tripathi S, Verma A, Kim EJ, et al. LL-37 modulates human neutrophil responses to influenza A virus. J Leukoc Biol 2014; 96: 931-938.
50. Goh BC, Rynkiewicz MJ, Cafarella TR, et al. Molecular mechanisms of inhibition of influenza by surfactant protein d revealed by large-scale molecular dynamics simulation. Biochemistry 2013; 52: 8527-8538.
51. Paquette SG, Banner D, Zhao Z, et al. Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLOS ONE 2012; 7: e38214-e38214.
52. Brown KL, Poon GF, Birkenhead D, et al. Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. J Immunol 2011; 186: 5497-5505.